Work

A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL)

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.6536

Authors: F. J. Giles, R. Larson, P. Le Coutre, M. Baccarani, R. Tavorath, L. Alland, H. M. Kantarjian, T. Hughes, O. Ottmann

Institutions: Royal Adelaide Hospital, University of Chicago, Charité – Universitätsmedizin Berlin, University of Bologna

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W168815251

Cites:

Cited by: 13

Related to: 10